- "The available clinical evidence does not support replacing the recommendation of trimethoprim-sulfa as first line therapy. However, considering the PK/PD findings, it is equally possible to conclude that in these studies suboptimal agents were compared to suboptimal agents" #idsky
- 🆕💫 New narrative review challenges the longstanding reliance on TMP-SMX for the treatment of Stenotrophomonas infections—citing PK/PD concerns and rising resistance. Also questions mono vs combo use. Clinical data still limited. Worth a close read #idsky www.sciencedirect.com/science/arti...